Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUEEN-APPLE: QL1706, Anlotinib, and Nab-Paclitaxel in First-Line Advanced TNBC
NCT07601178Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in triple-negative breast cancer (TNBC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Started Apr 2026; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07601178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601178.